Chasteberry / Vitex (Vitex agnus-castus): PMS, Prolactin & the Dopamine Connection — A Research-Backed Guide
⚡ 60-Second Summary
Chasteberry (Vitex agnus-castus) is the dried berry of a Mediterranean shrub with a well-characterised mechanism unlike most herbal supplements: its diterpene compounds act as dopamine D2 receptor agonists in the pituitary gland, directly reducing prolactin secretion. This is not a vague "hormone-balancing" claim — it is a specific pharmacological mechanism confirmed in multiple human trials.
Why prolactin matters for PMS: Elevated prolactin in the luteal phase of the menstrual cycle is associated with breast tenderness, mood changes, fluid retention, and other PMS symptoms. Prolactin suppression by chasteberry improves the luteal estrogen-to-progesterone ratio, reducing these symptoms. The effect is most pronounced in women with borderline elevated prolactin.
Clinical evidence: Three systematic reviews/meta-analyses (Schellenberg 2012, van Die 2013, He 2009) covering 8–12 RCTs consistently show that chasteberry reduces PMS and PMDD symptom severity. Evidence quality is moderate; most trials used proprietary extracts (Ze 440, BNO 1095).
Critical interactions: Do NOT combine with antipsychotics or dopamine agonists/antagonists. Use with caution with hormonal contraceptives. Not for use in pregnancy.
Typical dose: 20–40 mg standardised dry extract once daily in the morning. Allow 2–3 menstrual cycles for full effect.
What is chasteberry / vitex?
Vitex agnus-castus is a flowering shrub native to Mediterranean and Central Asian regions, known historically as the "chaste tree" because monks in medieval Europe reportedly used it to suppress libido. The supplement is derived from its small, pepper-like berries (hence the alternative name "monk's pepper"). In European phytomedicine, standardised Vitex extracts are among the most frequently prescribed herbal medicines for gynaecological complaints, and the German Commission E approved its use for irregularities of the menstrual cycle, PMS, and mastalgia in 1992.
Unlike most herbal supplements with poorly understood mechanisms, chasteberry has a defined molecular target: dopamine D2 receptors in the pituitary lactotroph cells that produce prolactin.
The dopamine–prolactin mechanism
The central pharmacological mechanism of chasteberry is now well-established in the scientific literature:
- Active diterpenes (rotundifuran, clerodadienols): These compounds bind D2 receptors on pituitary lactotroph cells.
- Prolactin suppression: D2 activation inhibits cAMP production in lactotrophs, reducing prolactin release. This is the same mechanism as pharmaceutical dopamine agonists bromocriptine and cabergoline — but at a much lower magnitude.
- Luteal phase correction: Lower prolactin in the luteal phase allows more robust progesterone secretion from the corpus luteum, improving the estrogen-to-progesterone ratio. Many women with PMS have subtle luteal-phase prolactin elevations.
- Opioid receptor activity: Some chasteberry compounds also show weak mu-opioid receptor activity, which may contribute to anti-pain and mood effects.
- Estrogen receptor modulation: Some diterpenes show weak estrogenic activity, though this is not the primary mechanism for PMS benefit.
This multi-receptor pharmacology is why chasteberry can influence breast tenderness (prolactin effect), mood changes (dopamine/opioid), and pain (opioid receptor), while the dominant clinical use is PMS and PMDD.
PMS and PMDD: what the meta-analyses show
Schellenberg et al. 2012 (Cochrane-style review)
This comprehensive review of 12 RCTs (n=1,634) found that standardised chasteberry extract (primarily Ze 440 at 20 mg/day and BNO 1095 at 40 mg/day) was significantly superior to placebo for reducing total PMS symptom scores. Response rates of 50% or greater symptom improvement were reported in 52–68% of verum participants versus 24–35% in placebo groups. The number-needed-to-treat (NNT) was approximately 4 — competitive with some pharmaceutical PMS treatments.
He et al. 2009 (meta-analysis)
Analysis of 8 RCTs found statistically significant reductions in PMS symptom scores, particularly for irritability, mood changes, breast tenderness, and headache. The evidence was strongest for these physical symptoms; emotional symptom improvement, while present, had wider confidence intervals.
Van Die et al. 2013
This systematic review also covered PMDD (premenstrual dysphoric disorder, the more severe classification) and found chasteberry comparable to SSRIs at improving PMDD symptom scores in the two head-to-head RCTs identified. These data are preliminary, and SSRIs remain first-line pharmacotherapy for PMDD — but the comparison is notable.
Time course
Clinical effect builds over 2–3 menstrual cycles. Trials of 3–6 months consistently show stronger effects than shorter trials, suggesting that patients who judge the supplement after just one cycle may underestimate its potential benefit.
Other uses: endometriosis, fertility, mastalgia
Mastalgia (breast pain): Chasteberry has a Commission E approval specifically for mastalgia. Two double-blind RCTs show significant reduction in cyclical breast pain, including comparison with bromocriptine and gestagens with similar efficacy and better tolerability. This is one of the most evidence-supported uses.
Infertility associated with luteal phase deficiency: A few small RCTs suggest that chasteberry may improve progesterone levels and pregnancy rates in women with luteal phase deficiency. The evidence is insufficient to recommend chasteberry as a primary fertility treatment, but it is sometimes used as an adjunct.
Endometriosis: Some observational data and clinical protocols include chasteberry as adjunct hormonal support. No adequate RCT specifically in endometriosis.
PCOS: Preliminary evidence only. Chasteberry is sometimes used in PCOS protocols to address luteal phase issues, but evidence for LH/FSH ratio normalisation or ovulation induction is insufficient for recommendations.
Dosage and proprietary extracts
| Product / Extract | Dose used in trials | Whole berry equivalent | Notes |
|---|---|---|---|
| Ze 440 (Prefemin) | 20 mg/day standardised extract | ~120 mg dried berry | Most studied single-ingredient extract. Available OTC in Europe. |
| BNO 1095 (Cyclodynon) | 40 mg/day | ~240 mg dried berry | Used in several large German RCTs including the landmark PMDD trial. |
| Generic dry extract (standardised) | 20–40 mg/day | 120–240 mg berry equivalent | Look for products specifying diterpene content or equivalent berry weight. |
| Whole berry powder | 480–1000 mg/day | Direct | Less consistent potency than standardised extract. Used in traditional protocols. |
| Tincture (1:5 ethanol extract) | 2–4 mL/day | Variable | Convenient but harder to standardise dose. |
Timing: Take once daily in the morning with water, before breakfast. Once-daily dosing in the morning is better established than split doses.
Safety and side effects
Chasteberry has an excellent safety record in trials up to 12 months. Most adverse effects are mild and transient.
- Mild GI effects: Nausea, upset stomach (rare at standard doses)
- Headache: Occasionally reported, particularly during initial use
- Skin reactions: Mild rash or itching in rare cases
- Menstrual cycle changes: Cycle length may temporarily shift as prolactin normalises — this is typically the therapeutic effect, not an adverse event
- Acne exacerbation: Rare, reported in some case reports
Pregnancy: do not use
Chasteberry must not be used during pregnancy. Its hormonal and dopaminergic activity during pregnancy is unpredictable, and animal data show reproductive effects. If pregnancy occurs during chasteberry use, discontinue immediately and consult an OB-GYN.
Hormone-sensitive conditions
People with hormone-sensitive conditions (hormone receptor-positive breast cancer, uterine fibroids, endometriosis with estrogenic sensitivity) should consult a specialist before using chasteberry due to its complex hormonal effects.
Drug interactions — the critical ones
| Drug class | Interaction type | Clinical significance |
|---|---|---|
| Antipsychotics (haloperidol, risperidone, quetiapine, aripiprazole) | Pharmacodynamic antagonism — chasteberry D2 agonism counteracts antipsychotic D2 blockade | HIGH — may reduce antipsychotic efficacy or worsen psychosis. Absolutely contraindicated without psychiatrist oversight. |
| Dopamine agonists (bromocriptine, cabergoline, pramipexole) | Additive dopaminergic effect | MODERATE–HIGH — additive prolactin lowering; potential for excessive dopaminergic effects. Do not combine. |
| Hormonal contraceptives (combined pill, progestin-only, hormonal IUD) | Interference with hormonal contraceptive mechanisms; theoretical prolactin/progesterone pathway alteration | MODERATE — possible interference; discuss with prescribing clinician. Not confirmed to cause contraceptive failure in clinical data, but the pharmacological rationale for caution is clear. |
| Metoclopramide, domperidone (dopamine antagonists used for GI motility/nausea) | Antagonism of GI dopamine blocking effect | MODERATE — may reduce effectiveness of these GI drugs |
Who might benefit — and who must avoid it
| Most likely to benefit | Must avoid or use only with specialist oversight |
|---|---|
| Women with moderate-to-severe PMS symptoms (particularly breast tenderness, mood changes, bloating) | Anyone taking antipsychotic medications |
| Women with PMDD seeking adjunct or first-line herbal support alongside lifestyle modifications | Pregnant women or those actively trying to conceive after ovulation |
| Women with cyclical mastalgia (cyclic breast pain) | People taking dopamine agonists or antagonists of any kind |
| Women with borderline elevated prolactin and luteal phase deficiency | Women on hormonal contraceptives (discuss with clinician first) |
Frequently asked questions
How does chasteberry work for PMS?
Via D2 receptor agonism in the pituitary, reducing prolactin secretion. Lower luteal prolactin improves progesterone secretion from the corpus luteum, correcting the estrogen-progesterone imbalance that drives PMS symptoms — breast tenderness, bloating, mood changes, and headache.
What is the recommended dose of chasteberry?
20–40 mg of standardised dry extract (Ze 440 at 20 mg or BNO 1095 at 40 mg) once daily in the morning. Allow 2–3 menstrual cycles for full benefit. Equivalent berry powder dose is 120–480 mg/day.
Can I take chasteberry with the pill or hormonal IUD?
Not without discussing with your clinician. Chasteberry's dopaminergic/hormonal activity can interact with hormonal contraceptives. While contraceptive failure has not been confirmed in clinical studies, the pharmacological interaction warrants medical supervision.
Does chasteberry interact with antipsychotic medications?
Yes — this is a critical, potentially serious interaction. Chasteberry acts as a D2 agonist; antipsychotics act as D2 antagonists. Combining them can reduce antipsychotic efficacy. Never use chasteberry alongside antipsychotics without psychiatrist oversight.
How long does chasteberry take to work for PMS?
Most clinical trials show benefits building over 2–3 menstrual cycles (2–3 months). Do not judge efficacy after just one cycle — this is a common mistake that leads to premature discontinuation of an otherwise effective supplement for an individual.
Related ingredients and articles
Magnesium
The first-line evidence-based mineral for PMS — often combined with vitex.
Evening Primrose Oil
GLA for mastalgia and PMS — how it compares to chasteberry.
PMS Supplements Ranked by Evidence
Vitex, magnesium, B6, calcium, evening primrose oil — honest comparison.
PMDD Treatment Options
Herbal and pharmaceutical approaches — when supplements fit and when they don't.
Disclaimer: This information is for educational purposes only and should not replace medical advice. Always consult a qualified healthcare provider before starting any supplement, especially if you have a medical condition, are pregnant, or take prescription medications. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.